F-1: Cuprina Holdings Eyes Nasdaq Listing with Initial Public Offering

Cuprina Holdings, a Singapore-based biomedical company, has filed for an initial public offering to list its Class A Ordinary Shares on the Nasdaq Capital Market.

Summary

• Cuprina Holdings (Cayman) Limited, a Singapore-based biomedical and biotechnology company, is planning an initial public offering (IPO) to list its Class A Ordinary Shares on the Nasdaq Capital Market under the ticker symbol CUPR.
• The company manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, used for chronic wound debridement.
• Cuprina also has collagen dressings and medical leech products in its development pipeline, expected to become commercially available in 2024 and 2025, pending regulatory approvals.
• For the years ended December 31, 2021 and 2022, revenue was S$58,504 and S$56,599 (US$42,094), respectively, with net losses of S$519,686 and S$1,094,516 (US$814,008).
• For the six months ended June 30, 2022 and 2023, revenue was S$27,951 and S$44,690 (US$32,965), respectively, with net losses of S$544,108 and S$452,648 (US$333,885).
• The company intends to use the IPO proceeds for market expansion, research and development, brand awareness, equipment investment, and loan repayment.
• Network 1 Financial Securities, Inc. is the underwriter for the IPO and will receive warrants to purchase 5% of the Class A Ordinary Shares sold in the offering.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing growth opportunities and has innovative products, it also faces financial challenges and risks associated with its operations and the regulatory environment.

Positives

• The company has strategic plans to expand sales and establish physical operations in Southeast Asia, the Middle East, and mainland China.
• The company has attained ISO 13485:2016 standards for its manufacturing facility in Singapore.
• The company has access to innovative technology in developing pipeline products through collaborations with Nanyang Technological University.
• The company has a loyal and growing customer base.

Negatives

• The company has a history of losses and expects to incur losses in the future.
• The company recorded net current liabilities as of December 31, 2021 and 2022 and June 30, 2023.
• The company had net operating cash outflows for the years ended December 31, 2021 and 2022 and six months ended June 30, 2023.
• The company's independent registered public accounting firm expressed substantial doubt regarding its ability to continue as a going concern.

Risks

• The company may not be able to achieve or sustain profitability.
• The company's revenue growth is difficult to predict.
• The company may not be able to develop new products that are competitive or successful.
• The company's pipeline products are still under development and may not be successfully commercialized.
• The company may be found to infringe on or violate the intellectual property rights of others.
• The company is subject to governmental regulations relating to the labeling, marketing and sale of its products.
• The company may not be able to obtain or maintain adequate reimbursement or insurance coverage for its medical products.
• The company is dependent on its key management and skilled personnel for its continued success and growth.
• The company is exposed to foreign exchange risks.
• The company is subject to credit risk arising from some of its customers.
• The company is dependent on a few of its major customers and suppliers.
• The reduction or discontinuation of government grants currently available to the company may have a material adverse effect on its business operations and financial condition.
• The company's historical growth and performance may not be indicative of its future growth and performance.
• The company's Class A Ordinary Shares could be subject to significant price volatility should its earnings fail to meet the expectations of investors.
• As a part of its business strategy, the company plans to expand its business operations into new geographic markets including mainland China and Hong Kong, which could subject it to rules, regulations and influence of regulators in those jurisdictions.
• The company will be a controlled company within the meaning of the rules of Nasdaq and, as a result, will rely on exemptions from certain corporate governance requirements that provide protection to shareholders of other companies.
• It may be difficult for you to enforce any judgment obtained in the United States against the company, its directors, executive officers or its affiliates.
• The ability of the company's subsidiary in Singapore to distribute dividends to it may be subject to restrictions under applicable laws.
• It is not certain if the company will be classified as a Singapore tax resident.
• Any adverse material changes to the Singapore market (whether localized or resulting from economic or other conditions) such as the occurrence of an economic recession, pandemic or widespread outbreak of an infectious disease (such as COVID-19), could have a material adverse effect on the company's business, results of operations and financial condition.
• An active trading market for the company's Class A Ordinary Shares may not be established or, if established, may not continue and the trading price for its Class A Ordinary Shares may fluctuate significantly.
• The company may not maintain the listing of its Class A Ordinary Shares on the Nasdaq which could limit investors ability to make transactions in Class A Ordinary Shares and subject it to additional trading restrictions.
• The trading price of the company's Class A Ordinary Shares may be volatile, which could result in substantial losses to investors.
• If securities or industry analysts do not publish research or reports about the company's business, or if they adversely change their recommendations regarding its Class A Ordinary Shares, the market price for its Class A Ordinary Shares and trading volume could decline.
• The company's corporate actions are significantly influenced by its directors, officers and principal shareholders, who have the ability to exert significant influence over important corporate matters that require approval of shareholders while their interests may differ from those of the other shareholders.
• The dual-class structure of the company's ordinary shares may adversely affect the trading market for its Class A Ordinary Shares.
• The sale or availability for sale of substantial amounts of its Class A Ordinary Shares could adversely affect their market price.
• The company's Class A Ordinary Shares could be subject to significant price volatility should its earnings fail to meet the expectations of investors.
• Because the company does not expect to pay dividends in the foreseeable future, you must rely on price appreciation of its Class A Ordinary Shares for a return on your investment.
• Because its public offering price per Class A Ordinary Shares is substantially higher than its net tangible book value per Class A Ordinary Shares, you will experience immediate and substantial dilution.
• You must rely on the judgment of the company's management as to the uses of the net proceeds from this offering, and such uses may not produce income or increase its share price.
• If the company is classified as a passive foreign investment company, United States taxpayers who own its securities may have adverse United States federal income tax consequences.
• The company may need additional capital, and it may be unable to obtain such capital in a timely manner or on acceptable terms, or at all.
• The company is an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements.
• The company is a foreign private issuer within the meaning of the Exchange Act, and as such it is exempt from certain provisions applicable to United States domestic public companies.
• As a company incorporated in the Cayman Islands, the company is permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards.
• The company may lose its foreign private issuer status in the future, which could result in significant additional costs and expenses to it.
• The company will incur significantly increased costs and devote substantial management time as a result of the listing of its Class A Ordinary Shares on the Nasdaq.
• You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because the company is incorporated under Cayman Islands law.
• If the company fails to maintain an effective system of internal controls over financial reporting, it may not be able to accurately report its financial results or prevent fraud and its business may be harmed and its stock price may be adversely impacted.
• Certain judgments obtained against the company by its shareholders may not be enforceable.

Future Outlook

The company plans to expand into new geographic markets, continue to expand its product portfolio through development and innovation, strengthen brand awareness, and acquire and retain customers.

Industry Context

The chronic wound care market is driven by an aging population and increasing comorbidities like diabetes and obesity, creating a growing demand for innovative and effective wound care solutions.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• However, it mentions competitors like Smith & Nephew plc, ConvaTec Group plc, Mlnlycke Health Care AB, 3M, Integra Urgo Group, and other local companies.

Related Party Transactions

• The company has related party transactions with Cuprina Holding Pte. Ltd., Jimmy Lee Peng Siew, and other related companies and individuals for working capital purposes and management services.
• Cuprina Holding Pte. Ltd. provided financial assistance to the company for working capital needs.
• Jimmy Lee Peng Siew provided advances to the company for working capital purposes.
• The company provided management services to Pestoniks Innovations Pte. Ltd.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the IPO and the dual-class share structure.
• Employees may be impacted by the company's ability to attract and retain skilled personnel.
• Customers may benefit from the company's innovative products and expansion into new markets.
• Suppliers may benefit from increased orders as the company grows.

Next Steps

• The company intends to apply for the listing of the Class A Ordinary Shares on the Nasdaq under the symbol CUPR.
• The company expects to receive a 510(k) clearance for its MEDIFLY products by the first half of 2024, subject to FDA enquiries or clarifications.
• The company intends to present its 510(k) submission to the FDA for its bullfrog collagen sponge dressings upon the receipt of the ISO 10993 biocompatibility test results, which it expects to be completed in the first half of 2024.
• The company plans to commence clinical trials in Singapore for its bullfrog sponge dressing in the second half of 2024.

Key Dates

Keywords

IPO, initial public offering, Cuprina Holdings, biomedical, biotechnology, Nasdaq, MEDIFLY, chronic wounds, maggot debridement therapy, collagen dressings, medical leeches, cosmeceuticals, Singapore